Last reviewed · How we verify
NCT07184788
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
Phase 2 trial testing Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy in Aggressive B-Cell Lymphoma in 80 participants. Not yet recruiting.
1 October 2030
Quick facts
| Lead sponsor | Navy General Hospital, Beijing |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 October 2025 |
| Primary completion | 1 October 2030 |
| Estimated completion | 1 October 2031 |
Drugs / interventions tested
- Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy — full drug profile →
Conditions studied
- Aggressive B-Cell Lymphoma — all drugs for Aggressive B-Cell Lymphoma →
Sponsor
Navy General Hospital, Beijing
Who can join
14 and older, any sex, with Aggressive B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07184788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Navy General Hospital, Beijing trials
Trials by the same sponsor.
- NCT06382038 — Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism · NA · not yet recruiting
- NCT06938893 — Study on Cardiac Output Evaluation Based on Wearable Monitoring Data · not yet recruiting
- NCT06744894 — SIL as Maintenance Therapy in Multiple Myeloma · Phase 2 · not yet recruiting
- NCT06350344 — Smart Technology Facilitated Patient-centered Venous Thromboembolism Management · NA · not yet recruiting
- NCT06176027 — Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07184788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Navy General Hospital, Beijing
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07184788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing